Evorpacept |
ALX148; ALX-148 |
Phase 3 Clinical |
Alexo Therapeutics |
Urinary Bladder Neoplasms; Neoplasm Metastasis; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Plasmablastic Lymphoma; Solid tumours; Carcinoma, Transitional Cell; Composite Lymphoma; Neoplasms; Myelodysplastic Syndromes; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Head and Neck Neoplasms |
Details
|
Lemzoparlimab |
TJC-4; ABBV-IMAB-TJC4; TJ-1133; TJ-011133 |
Phase 3 Clinical |
I-Mab Biopharma Co Ltd, Abbvie Inc |
Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma |
Details
|
Magrolimab |
5-F-9; Hu5F9-G4; ONO-7913 |
Phase 2 Clinical |
Stanford University |
Urinary Bladder Neoplasms; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Sezary Syndrome; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Osteosarcoma; Neuroblastoma; Brain Neoplasms; Multiple Myeloma; Solid tumours; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Leukemia, Lymphoid; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Ovarian Neoplasms; Lymphoma, B-Cell |
Details
|
Timdarpacept |
IMM01; IMM 01 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
AO-176 |
AO-176; Ti-104; Ti-108; Ti-176 |
Phase 2 Clinical |
Arch Oncology Inc |
Solid tumours; Multiple Myeloma |
Details
|
Ontorpacept |
TTI-621 |
Phase 2 Clinical |
The Hospital For Sick Children, University Health Network, Trillium Therapeutics Inc |
Multiple Myeloma; Mycosis Fungoides; Melanoma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Sarcoma; Breast Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leiomyosarcoma; Neoplasms; Papillomavirus Infections; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Merkel Cell; Hematologic Neoplasms; Solid tumours; Lymphoma, B-Cell |
Details
|
IMM-0306 |
IMC-002; IMM-0306 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
Ligufalimab |
AK-117 |
Phase 2 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma |
Details
|
Maplirpacept |
TTI-622; PF-07901801 |
Phase 2 Clinical |
Trillium Therapeutics Inc |
Hematologic Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute |
Details
|
DSP-107 |
DSP-107; KAHR-107 |
Phase 2 Clinical |
Kahr Medical |
Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung |
Details
|
LB-101 (Centessa Pharmaceuticals) |
LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody |
Phase 2 Clinical |
Centessa Pharmaceuticals Plc |
Solid tumours |
Details
|
ISB-1442 |
ISB 1442; ISB-1442 |
Phase 2 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
PT-886 |
PT-886; PT886 |
Phase 2 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
IMM-2902 |
IMM-2902 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Stomach Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms |
Details
|
6MW-3211 |
6MW3211; 6MW-3211 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma |
Details
|
HX-009 |
HX-009 |
Phase 2 Clinical |
Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma |
Details
|
CC-90002 |
INBRX-103; CC-90002 |
Phase 1 Clinical |
Inhibrx |
Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
Anti-CD47 monoclonal antibody (Biocad) |
|
Phase 1 Clinical |
Biocad |
Neoplasms |
Details
|
IMC-002(Immuneoncia) |
IMC-002; 3D-197; 3D197 |
Phase 1 Clinical |
Immuneoncia Therapeutics Inc |
Solid tumours; Hematologic Neoplasms; Neoplasms; Lymphoma; Neoplasm Metastasis |
Details
|
Recombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology) |
MIL-95; CM-312 |
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma |
Details
|
Zeripatamig |
NI-1701; TG-1801 |
Phase 1 Clinical |
Novimmune Sa |
Lymphoma, B-Cell |
Details
|
SL-172154 |
SL-172154 |
Phase 1 Clinical |
Shattuck Labs Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute |
Details
|
Urabrelimab |
SRF-231 |
Phase 1 Clinical |
Surface Oncology Inc |
Hematologic Neoplasms; Solid tumours |
Details
|
Simridarlimab |
IBI-322; IBI322 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Hematologic Neoplasms; Solid tumours; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell |
Details
|
ZL-1201 |
ZL-1201 |
Phase 1 Clinical |
Zai Lab (Shanghai) Co Ltd |
Hematologic Neoplasms; Solid tumours; Neoplasms |
Details
|
AUR-103 |
AUR-103 |
Phase 1 Clinical |
Aurigene |
Leukemia; Solid tumours; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute |
Details
|
HMPL-A83 |
HMPL-A-83; HMPL-A83 |
Phase 1 Clinical |
Hutchison Medipharma Ltd |
Solid tumours; Hematologic Neoplasms; Neoplasms |
Details
|
NI-1801 |
NI-1801 |
Phase 1 Clinical |
|
Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung |
Details
|
AK-132 |
AK132; AK-132 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
HCB-101 |
HCB-101 |
Phase 1 Clinical |
HanchorBio Inc |
Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
D3L-001 |
D3L-001 |
Phase 1 Clinical |
D3 Bio (Wuxi) Co Ltd |
Solid tumours; Neoplasms |
Details
|
FP-002 (Fapon Biopharma) |
FP-002 |
Phase 1 Clinical |
Fapon Biotech Inc |
Solid tumours; Neoplasms |
Details
|
AUR-105 |
AUR-105 |
Phase 1 Clinical |
Aurigene |
Solid tumours; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
BC-007 (Dragonboat Biopharmaceutical) |
BC-007 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical |
Solid tumours; Neoplasms |
Details
|
BSI-082 |
BSI-082 |
Phase 1 Clinical |
Boaoxin Biotechnology(Nanjing) Co Ltd |
Hematologic Neoplasms; Solid tumours |
Details
|
SG-1906 |
SG-1906; SG1906 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
SG-2501 |
SG-2501 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Lymphoma |
Details
|
PT-217 |
PT-217 |
Phase 1 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine |
Details
|
LD-002 |
LD-002 |
Phase 1 Clinical |
Zhejiang Blue Shield Pharmaceutical Co Ltd |
Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
SHS-009 |
SHS-009; SH009; SH-009 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Monoclonal Antibody (Mab) sB24M |
|
Phase 1 Clinical |
Swiss Biopharma Med GmbH |
Pyoderma Gangrenosum; Pyoderma |
Details
|
IMM-2520 |
IMM-2520 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BAT-7104 |
BAT-7104 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Neoplasms |
Details
|
STI-6643 |
STI-6643 |
Phase 1 Clinical |
Sorrento Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
PF-07257876 |
|
Phase 1 Clinical |
Pfizer Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
TQB-2928 |
TQB-2928 |
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute |
Details
|
JMT-601 |
JMT-601 |
Phase 1 Clinical |
Shanghai Jmt-Bio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
IMM2505 |
IMM2505; IMM-2505 |
Phase 1 Clinical |
SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
SG12473 |
SG12473; SG-12473 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours; Neoplasms |
Details
|
SG404 |
SG-404; SG404 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Neoplasms |
Details
|
Kintuzumab(GenSci) |
|
Phase 1 Clinical |
Changchun GeneScience Pharmaceuticals Co Ltd |
Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma |
Details
|
Letaplimab |
IBI-188 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Adenocarcinoma of Lung; Neoplasms; Myelodysplastic Syndromes; Osteosarcoma; Leukemia, Myeloid, Acute |
Details
|